

02-06-02

A

PATENT

Attorney Docket No. 0236.0018

02/04/02  
J1054 U.S. PTO

1c979 U.S. PTO  
10/06/181  
02/04/02

Box Patent Application  
Commissioner of Patents and Trademarks  
Washington, D.C. 20231

### NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of  
Inventor(s):

David A. Martin and David R. Montgomery

WARNING: Patent must be applied for in the name(s) of all of the actual inventor(s). 37 CFR  
1.41(a) and 1.53(b).

For (title): **CREDENTIALER/MEDICAL MALPRACTICE INSURANCE  
COLLABORATION**

#### 1. Type of Application

This new application is for a(n) (check one applicable item below):

☒ Original

☐ Design

☐ Plant

WARNING: Do not use this transmittal for a completion in the U.S. of an International  
Application under 35 U.S.C. 371(c)(4) unless the International Application is being filed as a  
divisional, continuation or continuation-in-part application.

NOTE: If one of the following 3 items apply then complete and attach ADDED PAGES FOR  
NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S.  
APPLICATION CLAIMED.

☐ Divisional

\_\_\_\_ Continuation

  X   Continuation-in-part (CIP)

**CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date 2/4/02 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EJ 02509125403 addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Shelly L. Porter  
Shelly L. Porter

Shelly L. Porter  
Shelly L. Porter

NOTE: Each paper or fee referred to as enclosed herein has the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 CFR 1.10(b).

**2. Benefit of Prior U.S. Application(s) (35 USC 120)**

NOTE: If the new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or where the parent case is an International Application which designated the U.S., then check the following item and complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

  X   The new application being transmitted claims the benefit of U.S. Serial No. 09/339,479, entitled **CREDENTIALER/MEDICAL MALPRACTICE INSURANCE COLLABORATION**, filed June 24, 1999.

**3. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Regular) or 37 CFR 1.153 (Design) Application**

13 Pages of specification

4 Pages of claims

1 Pages of Abstract

0 Sheets of drawing

     formal

     informal

WARNING: DO NOT submit original drawings. A high quality copy of the drawings should be supplied when filing a patent application. The drawings that are submitted to the Office must be on strong, white, smooth, and non-shiny paper and meet the standards according to 1.84. If corrections to the drawings are necessary, they should be made to the original drawing and a high-quality copy of the corrected original drawing then submitted to the Office. **Only one copy is required or desired.** Comments on proposed new 37 CFR 1.84, Notice of March 9, 1988 (1990 O.G. 57-62).

NOTE: "Identifying indicia such as the serial number, group and unit, title of the invention, attorney's docket number, inventor's name, number of sheets, etc., not to exceed 2 3/4 inches (7.0 cm.) in width may be placed in a centered location between the side edges within three fourths inch (19.1 mm.) of the top edge. Either this marking technique on the front of the drawing or the placement, although not preferred, of this information and the title of the invention on the back of the drawings is acceptable." Proposed 37 CFR 1.84(1). Notice of March 9, 1988 (1090 O.G. 57-62).

#### 4. Additional papers enclosed

     Preliminary Amendment

     Information Disclosure Statement

     Form PTO-1449

     Citations

\_\_\_\_ Declaration of Biological Deposit

\_\_\_\_ Submission of "Sequence Listing", computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.

\_\_\_\_ Authorization of Attorney(s) to Accept and Follow instructions from Representative

\_\_\_\_ Special Comments

\_\_\_\_ Other

## 5. Declaration or oath

☒ Enclosed  
executed by (check all applicable boxes)

☒ inventor(s)

\_\_\_\_ legal representative of inventor(s). 37 CFR 1.42 or 1.43

\_\_\_\_ joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.

\_\_\_\_ this is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached. See item 13 below for fee.

\_\_\_\_ Not Enclosed.

WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is not available or where the completion of the U.S. application contains subject matter in addition to the International Application the application may be treated as a continuation or continuation-in-part, as the case may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION CLAIMED.

\_\_\_\_ Application is made by a person authorized under 37 CFR 1.41 on behalf of all the above named inventor(s). The declaration or oath, along with the surcharge required by 37 CFR 1.16(e) can be filed subsequently.

NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41 and 1.53(b).

\_\_\_\_ Showing that the filing is authorized. (Not required unless called into question. 37 CFR 1.41(d).

2006-03-09 10:00:00

**6. Inventorship Statement**

WARNING: If the named inventors are each not the inventors of all the claims an explanation, including the ownership of the various claims at the time the last claimed invention was made, should be submitted.

The inventorship for all the claims in this application are:

☒ The same

or

☐ Are not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,

☐ is submitted.

☐ will be submitted.

**7. Language**

NOTE: An application including a signed oath or declaration may be filed in a language other than English. A verified English translation of the non-English language application and the processing fee of \$30.00 required by 3 CFR 1.17(k) is required to be filed with the application or within such time as may be set by the Office. 37 CFR 1.52(d).

NOTE: A non-English oath or declaration in the form provided or approved by the PTO need not be translated. 37 CFR 1.69(b).

☒ English

☐ non-English

☐ the attached translation is a verified translation. 37 CFR 1.52(d).

**8. Assignment**

☒ An assignment of the invention to The Premium Group, Inc. of Cleveland, Ohio

☐ is attached.

☒ will follow.

204020-121-020402

NOTE: "If an assignment is submitted with a new application, send two separate letters-one for the application and one for the assignment." Notice of May 4, 1990 (1114 O.G. 77-78).

## 9. Certified Copy

Certified copy(ies) of application(s)

_____	_____	_____ (country)
(appln. no.)	(filed)	
_____	_____	_____ (country)
(appln. no.)	(filed)	
_____	_____	_____ (country)
(appln. no.)	(filed)	

from which priority is claimed

\_\_\_\_\_ is (are) attached. A separate "ASSIGNMENT COVER LETTER ACCOMPANYING NEW PATENT APPLICATION" is also attached.

\_\_\_\_\_ will follow.

NOTE: The foreign application forming the basis for the claim for priority must be referred to in the oath or declaration. 37 CFR 1.55(a) and 1.63.

NOTE: This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C. 120 is itself entitled to priority from a prior foreign application then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

## 10. Fee Calculation (37 CFR 1.16)

A. ☒ Regular application

### CLAIMS AS FILED

Number filed	Number Extra	Rate	Basic Fee
			\$710.00
<hr/>			
Total			
Claims 37 CFR 1.16	13-20=	X \$18.00	\$ 0.00
<hr/>			
Independent			

Claims (37 CFR 1.16(b)) 3-3= X \$78.00 \$0.00

---

Multiple dependent claim(s), if any  
(37 CFR 1.16(d)) \$260.00 \$ 0.00

---

\_\_\_\_ Amendment canceling extra claims enclosed.

\_\_\_\_ Amendment deleting multiple-dependencies enclosed.

\_\_\_\_ Fee for extra claims is not being paid at this time.

NOTE: If the fees for extra claims are not paid on filing they must be paid or the claims canceled by amendment, prior to the expiration of the time period set for response by the Patent and Trademark Office in any notice of fee deficiency. 37 CFR 1.16(d).

**B. \_\_\_\_ Design application**

(\$330.00--37 CFR 1.16(f))

Filing Fee Calculation\$ \_\_\_\_\_

**C. \_\_\_\_ Plant application**

(\$540.00--37 CFR 1.16(g))

Filing Fee Calculation\$ \_\_\_\_\_

**11. Small Entity Statement(s)**

  X   Applicant is a small entity under 37 CFR 1.9 and 1.27.

Filing Fee Calculation (50% of A,B or C above) \$ 355.00

NOTE: Any excess of the full fee paid will be refunded if a verified statement and a refund request are filed within 2 months of the date of timely payment of a full fee. 37 CFR 1.28(a).

**12. Request for International-Type Search (37 CFR 1.104(d)) (complete, if applicable)**

\_\_\_\_ Please prepare an international-type search report for this application at the time when national examination on the merits takes place.

**13. Fee Payment Being Made At This Time**

\_\_\_\_ Not Enclosed

\_\_\_\_ No filing fee is to paid at this time. (This and the surcharge required by 37 CFR 1.16(e) can be paid subsequently).

2025-03-23 10:23:23

☒ Enclosed

☒ basic filing fee \$ 355.00

☐ recording assignment \$ \_\_\_\_\_

((\$8.00; 37 CFR 1.21(h))

☐ petition fee for filing by other  
than all the inventors or person  
on behalf of the inventor where  
inventor refused to sign or cannot  
be reached. (\$120.00; 37 CFR 1.47  
and 1.17(h)) \$ \_\_\_\_\_

☐ for processing an application with  
a specification in a non-English  
language. (\$30.00; 37 CFR 1.52(d)  
and 1.17(k)) \$ \_\_\_\_\_

☐ processing and retention fee  
(\$120.00; 37 CFR 1.53(d) and  
1.21(l)) \$ \_\_\_\_\_

☐ fee for international-type search  
report (\$30.00; 37 CFR 1.21(e)). \$ \_\_\_\_\_

NOTE: 37 CFR 1.21(l) establishes a fee for processing and retaining any application which is abandoned for failing to complete the application pursuant to 37 CFR 1.53(d) and this, as well as the changes to 37 CFR 1.53 and 1.78, indicate that in order to obtain the benefit of a prior U.S. application, either the basic filing fee must be paid or the processing and retention fee of 1.21(l) must be paid within 1 year from notification under 53(d).

**Total fees enclosed** \$ 355.00

#### 14. Method of Payment of Fees

☒ Check in the amount of \$ 355.00



\_\_\_\_ Charge Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_.  
A duplicate of this transmittal is attached.

NOTE: Fees should be itemized in such a manner that it is clear for which purpose the fees are paid. 37 CFR 1.22(b).

### 15. Authorization to Charge Additional Fees

**WARNING:** If no fees are to be paid on filing the following items should not be completed.

**WARNING:** Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges, if extra claim charges are authorized.

  X   The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 05-0875.

  X   37 CFR 1.16(a), (f) or (g) (filing fees)

  X   37 CFR 1.16(b), and (d) (presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or these claims canceled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 CFR 1.16(d)), it might be best not to authorize the PTO to charge additional claim fees, except possibly when dealing with amendments after final action.

  X   37 CFR 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)

  X   37 CFR 1.17 (application processing fees)

**WARNING:** While 37 CFR 1.17(a), (b), (c), and (d) deal with extensions of time under 1.136(a) this authorization should be made only with the knowledge that: "Submission of the appropriate extension fee under 37 C.F.R. 1.136(a) is to no avail unless a request or petition for extension is filed." (Emphasis added). Notice of November 5, 1985 (1060 O.G. 27).

       37 CFR 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 CFR 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 CFR 1.311(b).

NOTE: 37 CFR 1.28(b) requires "Notification of any change in loss of entitlement to small

2005-03-01 10:05:00

entity status must be filed in the application... prior to paying, or at the time of paying...issue fee." From the wording of 37 CFR 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

# 16. Instructions As To Overpayment

\_\_\_\_\_ credit Account No. \_\_\_\_\_

  X   refund

Reg. No. 44,022

Tel. No. (330) 535-9999

Heather M. Barnes  
SIGNATURE OF ATTORNEY

Heather M. Barnes  
Emerson & Skeriotis  
One Cascade Plaza--Fourteenth Floor  
Akron, OH 44308-1147

\_\_\_\_\_ Incorporation by reference of added pages

Check the following item if the application in this transmittal claims the benefit of prior U.S. application(s) (including an international application entering the U.S. stage as a continuation, divisional or C-I-P application) and complete and attach the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED

\_\_\_\_\_ Plus Added Pages For New Application Transmittal Where Benefit Of Prior U.S. Application(s) Claimed

Number of pages added \_\_\_\_\_

\_\_\_\_\_ Plus Added Pages For Papers Referred To In item 4 above

Number of pages added \_\_\_\_\_

\_\_\_\_\_ Plus "Assignment Cover Letter Accompanying New Application"

Number of pages added \_\_\_\_\_

2007-03-20 10:40:40

\_\_\_\_ Statement Where No Further Pages Added

(If no further pages form a part of this Transmittal then end this Transmittal with this page and check the following item)

  X   This transmittal ends with this page.

L:\0200-0299\236\0018\PTO\010329.dat.NEWTRANSAPP.doc

2006 FEB 29 00:00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David A. Martin and David R. Montgomery

For: CREDENTIALER / MEDICAL MALPRACTICE INSURANCE COLLABORATION Docket No.: 0236.0018

Serial No.: Unknown Art Unit: Unknown

Filed: herewith Examiner: Unknown

Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

\*\*\*\*\*

**CERTIFICATE OF MAILING (37 CFR 1.8a)**

I hereby certify that this **ASSOCIATE POWER OF ATTORNEY** is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

2/4/02  
Date

Shelly Porter

\*\*\*\*\*

**ASSOCIATE POWER OF ATTORNEY**

Dear Sir:

In the matter of the above-identified application, please recognize Marcella R. Louke (Registration No. 41,163), John M. Skeriotis (Registration No. 43,129), Timothy D. Bennett (Registration No. 42,312), Daniel A. Thomson (Registration No. 43,189), Timothy D. Smith (Registration No. P-50,880), Heather M. Barnes (Registration No. 44,022), Frederick K. Lacher (Registration No. 16,502), and Timothy S. Downs (Registration No. P-50,529) of Emerson & Skeriotis, One Cascade Plaza - Fourteenth Floor, Akron, Ohio 44308, as my associate attorneys or agents, with full power to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

All communications are to be addressed to Emerson & Skeriotis, One Cascade Plaza - Fourteenth Floor, Akron, Ohio 44308.

2/4/02  
Date

Roger D. Emerson  
Roger D. Emerson, Reg. No. 33,169  
Attorney for Applicant(s)